Cargando…
Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
Antibody-based therapy has revitalized the world of cancer therapeutics since rituximab was first approved for the treatment of Non-Hodgkin’s Lymphoma. Monoclonal antibodies against cancer antigens have been successful strategies for only a handful of cancer types due to many reasons including lack...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154901/ https://www.ncbi.nlm.nih.gov/pubmed/30249178 http://dx.doi.org/10.1186/s10020-018-0051-4 |